Literature DB >> 16828831

Antiretroviral potential of human tripartite motif-5 and related proteins.

Fengwen Zhang1, Theodora Hatziioannou, David Perez-Caballero, David Derse, Paul D Bieniasz.   

Abstract

TRIM5alpha is a potent inhibitor of infection by diverse retroviruses and is encoded by one of a large family of TRIM genes. We found that several TRIM motifs among a panel of selected human TRIM proteins (TRIM1, 5, 6, 18, 19, 21 22, 34) could inhibit infection when artificially targeted to an incoming HIV-1 capsid. Conversely, when ectopically expressed as authentic full-length proteins, most lacked activity against a panel of retroviruses. The exceptions were TRIM1, TRIM5 and TRIM34 proteins. Weak but specific inhibition of HIV-2/SIV(MAC) and EIAV by TRIM34 was noted, and human TRIM5alpha modestly, but specifically, inhibited an HIV-1 strain carrying a mutation in the cyclophilin binding loop (G89V). Restriction activity observed in ectopic expression assays was sometimes not detectable in corresponding RNAi-based knockdown experiments. However, endogenous owl monkey TRIMCyp potently inhibited an SIV(AGM) strain. Overall, sporadic examples of intrinsic antiretroviral activity exist in this panel of TRIM proteins.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16828831     DOI: 10.1016/j.virol.2006.05.035

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  76 in total

1.  Modulation of TRIM5alpha activity in human cells by alternatively spliced TRIM5 isoforms.

Authors:  Emilie Battivelli; Julie Migraine; Denise Lecossier; Saori Matsuoka; Danielle Perez-Bercoff; Sentob Saragosti; François Clavel; Allan J Hance
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

2.  Differential sensitivities of retroviruses to integrase strand transfer inhibitors.

Authors:  Yasuhiro Koh; Kenneth A Matreyek; Alan Engelman
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

Review 3.  Cyclophilin A, TRIM5, and resistance to human immunodeficiency virus type 1 infection.

Authors:  Jeremy Luban
Journal:  J Virol       Date:  2006-09-06       Impact factor: 5.103

4.  Functional interplay between the B-box 2 and the B30.2(SPRY) domains of TRIM5alpha.

Authors:  Xing Li; Byeongwoon Song; Shi-Hua Xiang; Joseph Sodroski
Journal:  Virology       Date:  2007-05-31       Impact factor: 3.616

Review 5.  Host restriction factors blocking retroviral replication.

Authors:  Daniel Wolf; Stephen P Goff
Journal:  Annu Rev Genet       Date:  2008       Impact factor: 16.830

6.  Determinants of cyclophilin A-dependent TRIM5 alpha restriction against HIV-1.

Authors:  Tsai-Yu Lin; Michael Emerman
Journal:  Virology       Date:  2008-08-03       Impact factor: 3.616

Review 7.  Molecular evolution of the antiretroviral TRIM5 gene.

Authors:  Welkin E Johnson; Sara L Sawyer
Journal:  Immunogenetics       Date:  2009-02-24       Impact factor: 2.846

8.  Adaptation to the interferon-induced antiviral state by human and simian immunodeficiency viruses.

Authors:  Julia Bitzegeio; Marissa Sampias; Paul D Bieniasz; Theodora Hatziioannou
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

9.  Protection afforded by an HIV vaccine candidate in macaques depends on the dose of SIVmac251 at challenge exposure.

Authors:  Monica Vaccari; Brandon F Keele; Steven E Bosinger; Melvin N Doster; Zhong-Min Ma; Justin Pollara; Anna Hryniewicz; Guido Ferrari; Yongjun Guan; Donald N Forthal; David Venzon; Claudio Fenizia; Tia Morgan; David Montefiori; Jeffrey D Lifson; Chris J Miller; Guido Silvestri; Margherita Rosati; Barbara K Felber; George N Pavlakis; James Tartaglia; Genoveffa Franchini
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

10.  Contribution of PDZD8 to stabilization of the human immunodeficiency virus type 1 capsid.

Authors:  Charles Alexander Guth; Joseph Sodroski
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.